EXACT Sciences Co. (NASDAQ:EXAS) – Research analysts at Jefferies Financial Group issued their Q1 2020 EPS estimates for shares of EXACT Sciences in a research note issued to investors on Wednesday, May 1st. Jefferies Financial Group analyst B. Couillard anticipates that the medical research company will post earnings per share of ($0.30) for the quarter. Jefferies Financial Group has a “Buy” rating and a $115.00 price objective on the stock. Jefferies Financial Group also issued estimates for EXACT Sciences’ Q2 2020 earnings at ($0.30) EPS, Q4 2020 earnings at ($0.30) EPS, Q1 2021 earnings at ($0.10) EPS and FY2022 earnings at $1.78 EPS.
EXAS has been the topic of a number of other research reports. Canaccord Genuity raised their price objective on shares of EXACT Sciences from $87.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, January 14th. Zacks Investment Research downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, February 13th. William Blair reissued an “outperform” rating on shares of EXACT Sciences in a report on Monday, January 7th. UBS Group raised their price objective on shares of EXACT Sciences from $109.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, April 16th. Finally, Robert W. Baird raised their price objective on shares of EXACT Sciences from $90.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, February 21st. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $108.45.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). The business had revenue of $162.00 million during the quarter, compared to analysts’ expectations of $153.07 million. EXACT Sciences had a negative return on equity of 29.47% and a negative net margin of 41.58%. The business’s quarterly revenue was up 79.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.33) EPS.
A number of large investors have recently modified their holdings of EXAS. Dimensional Fund Advisors LP lifted its holdings in EXACT Sciences by 2.6% during the third quarter. Dimensional Fund Advisors LP now owns 247,305 shares of the medical research company’s stock valued at $19,513,000 after purchasing an additional 6,186 shares in the last quarter. Man Group plc bought a new stake in shares of EXACT Sciences during the third quarter valued at approximately $728,000. Mackenzie Financial Corp raised its position in shares of EXACT Sciences by 23.6% during the third quarter. Mackenzie Financial Corp now owns 5,121 shares of the medical research company’s stock valued at $404,000 after buying an additional 978 shares during the last quarter. Vanguard Group Inc raised its position in shares of EXACT Sciences by 2.6% during the third quarter. Vanguard Group Inc now owns 10,498,087 shares of the medical research company’s stock valued at $828,509,000 after buying an additional 261,239 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in shares of EXACT Sciences during the fourth quarter valued at approximately $286,000. 89.84% of the stock is currently owned by institutional investors and hedge funds.
In other EXACT Sciences news, CFO Jeffrey Thomas Elliott sold 2,447 shares of EXACT Sciences stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $93.20, for a total transaction of $228,060.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Kevin T. Conroy sold 9,169 shares of EXACT Sciences stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $95.07, for a total transaction of $871,696.83. Following the transaction, the insider now directly owns 923,961 shares in the company, valued at approximately $87,840,972.27. The disclosure for this sale can be found here. Insiders have sold 60,201 shares of company stock worth $5,543,493 in the last ninety days. Insiders own 3.20% of the company’s stock.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Further Reading: Trading Strategy Examples and Plans
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.